Connect with us

Government

Futures Soars Above 3,400 To All Time High On Covid Plasma Treatment Approval

Futures Soars Above 3,400 To All Time High On Covid Plasma Treatment Approval

Published

on

Futures Soars Above 3,400 To All Time High On Covid Plasma Treatment Approval Tyler Durden Mon, 08/24/2020 - 07:58

You knew it was coming when Trump scheduled his news conference to announce the FDA's emergency authorization for convalescent plasma as a treatment for Covid-19 at 530pm on Sunday afternoon, half an hour before futures opened, and sure enough shortly after futures levitated to all time highs, hitting a record 3,422 moments ago, with European stocks rallying to a one-week high.

The FDA's decision to use plasma from recovered patients was hailed by President Donald Trump and came a day after he accused it of impeding the rollout of treatments for political reasons. Further aiding market sentiment, was a report that the Trump administration is considering fast-tracking an experimental COVID-19 vaccine being developed by AstraZeneca for use in the United States before election. The news came on the eve of the Republican National Convention in which Trump will be nominated to lead his party for four more years, kicking off the final sprint to Nov. 3 Election Day.

US travel stocks, including American Airlines, United Airlines and Carnival all rose in pre-market trading. Meanwhile, the next phase of coronavirus government aid remained elusive as top Democrats and Republicans continued to blame each other for stalled talks on the legislation.

European equities extended opening gains, following US futures, and driven by the progress of various potential coronavirus treatments. Euro Stoxx 50 saw a broad base for 2.3% gain, with oil & gas, chemical and tech names outperforming. Telecom carrier BT Group jumped after Sky News reported that the board is on alert for takeover approaches.

Asian stocks also gained, led by communications and materials, getting a boost after a report that White House officials have reassured American businesses that a ban on its WeChat app won’t be as broad as feared. WeChat owner Tencent Holdings jumped the most in a month, gaining $37 billion. The Topix gained 0.2%, with TEMONA and St-Care HD rising the most. The Shanghai Composite Index rose 0.1%, with Suzhou Harmontronics and Shenyang Jinshan Energy posting the biggest advances. China's ChiNext index reverses early drop to jump as much as 2.4% following sizzling tech IPOs and a trading-rule revamp to double daily price limits to 20%.

In commodities, Gold shrugged off its earlier losses to climb with copper and oil, while the dollar weakened. Crude was modestly higher with storms Marco and Laura are rolling toward the U.S. Gulf Coast, where they’ll come ashore as hurricanes as soon as Monday. Almost 58% of crude output in the U.S. Gulf of Mexico production has been shut down as the threat prompted evacuations of off-shore energy platforms and set residents and officials on edge from Texas to Florida.

In FX, the dollar fell as much as 0.3% with Goldman saying the case for USD depreciation remaining intact citing factors including USD being overvalued and US real interest rates to remain negative for several years, while it further cited a steady recovery of the economy from the pandemic. However, it also noted factors for consolidation to persist which includes pandemic uncertainty, Fed outlook and US politics.

Scandinavian currencies and the Aussie dollar led G-10 gains. The New Zealand dollar fell against most G-10 peers as a lockdown in the country’s largest city was extended. The country’s benchmark 10-year bond yield fell to hit a record mid- year low, after the central bank QE buying operation fell short of target. The euro held above $1.18 as investors showed interest to buy the common currency on any dips. One-week bullish sentiment in the euro slipped to its lowest in almost two months earlier on, as the dollar’s major peers enter correction mode in the cash market.

A key event this week would be the address by Fed Chair Jerome Powell at the Kansas City Fed Jackson Hole symposium, where he will talk on Thursday about the Fed’s long-awaited monetary policy framework review, which has focused on a new inflation strategy.

“We’re hoping to get some sort of hints as to where their fundamental view is going and there’s a lot of expectations around that,” said Marvin Barth, global head of foreign exchange and emerging markets macro strategy at Barclays Plc.

Also this week we get earnings from companies including, ICBC, PetroChina, HP Inc., Royal Bank of Canada, Best Buy and Dollar General. The U.S. Republican National Convention takes place, with Trump speaking the final day, Aug. 27. On today's calendar we get the Chicago Fed National Activity Index, while Palo Alto Networks is reporting earnings.

Market Snapshot

  • S&P 500 futures up 0.7% to 3,417.50
  • STOXX Europe 600 up 1.5% to 370.38
  • MXAP up 0.8% to 172.09
  • MXAPJ up 1.1% to 569.42
  • Nikkei up 0.3% to 22,985.51
  • Topix up 0.2% to 1,607.13
  • Hang Seng Index up 1.7% to 25,551.58
  • Shanghai Composite up 0.2% to 3,385.64
  • Sensex up 1% to 38,834.70
  • Australia S&P/ASX 200 up 0.3% to 6,129.57
  • Kospi up 1.1% to 2,329.83
  • German 10Y yield rose 1.8 bps to -0.489%
  • Euro up 0.1% to $1.1813
  • Italian 10Y yield rose 3.0 bps to 0.819%
  • Spanish 10Y yield rose 2.0 bps to 0.318%
  • Brent futures up 0.7% to $44.65/bbl
  • Gold spot up 0.3% to $1,947.09
  • U.S. Dollar Index down 0.2% to 93.03

Top Overnight News from Bloomberg

  • U.S. President Donald Trump said a treatment based on blood plasma donated by people who’ve recovered from Covid-19 will be expanded, even before researchers fully understand how well it works. Infections in the U.S. eased, while Europe is seeing a resurgence of cases
  • The Trump administration is privately seeking to reassure U.S. companies including Apple Inc. that they can still do business with the WeChat messaging app in China, according to several people familiar with the matter, two weeks after President Donald Trump ordered a U.S. ban on the Chinese- owned service
  • Two hurricanes are expected to hit the U.S. gulf coast as soon as Monday. Offshore energy platforms were evacuated as the storms approached

Asian equity markets traded mostly positive and E-mini S&P topped the 3,400 mark following Friday’s tech-fuelled gains on Wall St and the recent emergency use authorization of convalescent plasma for treatment of COVID-19 which was suggested to reduce mortality by 35%, but with gains capped by US-China decoupling concerns following comments by US President Trump. ASX 200 (+0.3%) and Nikkei 225 (+0.3%) were initially indecisive before outperformance in tech then proved to be the deciding factor to keep stocks afloat in Australia and with earnings results the main catalyst for the biggest stock movers, while the Japanese benchmark was also higher as it made another attempt at the 23,000 focal point. Hang Seng (+1.7%) and Shanghai Comp. (+0.2%) were underpinned by another firm liquidity effort by the PBoC, although gains in the mainland were tempered by the ongoing US-China tensions after President Trump raised the prospect of decoupling from China and suggested the US does not have to do business with China. In addition, the People’s Liberation Army are to conduct military drills across 3 major Chinese sea regions in the approaching days which is aimed at deterring Taiwan secessionists and the US, while increased IPO activity also attracts funds from the broader market with 18 firms listing in the ChiNext today as part of reforms in the tech board aimed at fast-tracking IPOs and which saw some of the newly-listed names surge as much as 500%. Finally, 10yr JGBs were positive despite the mild gains in stocks as prices tracked recent upside in T-notes and with the BoJ also present in the market for a total of JPY 450bln of JGBs predominantly concentrated in 3yr-5yr maturities.

Top Asian News

  • Japan’s Abe Visits Hospital Again Amid Speculation About Health
  • AMP Chair Murray Quits, Pahari Demoted After Investor Revolt
  • Delivery Giant Meituan Soars Most Since March After Sales Beat
  • Tourist Hotspot Bali to Stay Closed to Foreign Visitors All Year

European equities kick the week off on a firm footing (Euro Stoxx 50 +1.8%) as the region picked up the baton from a similarly positive APAC session. Some attribute upside in stocks, and generally firmer sentiment, to the US FDA authorising the emergency use of convalescent plasma as a treatment for hospitalised COVID-19 patients, but the FDA indicated that more trials are needed to prove its effectiveness. It is also worth keeping in mind that against the backdrop of global monetary and fiscal stimulus, a lack of “bad news” can be sufficient to support equity sentiment, particularly during thinned holiday trading. Furthermore, the US and the EU have signed a “mini-deal” in which the EU agreed to eliminate tariffs on US lobsters in exchange for the US halving import taxes on around USD 160mln worth of European goods. Although, the size seems relatively small, the deal signals a shift in sentiment between the two nations, which provides scope for further potential agreements between the two sides. A slight dichotomy is seen between the European and US index futures, with the former outperforming the state-side contracts, potentially due to (to some degree) tail risks heading into Fed’s Jackson Hole Symposium, US GDP and PCE releases this week, alongside stalled fiscal stimulus talks. Sectors are all higher but provide little by way of a bias, with Oil & Gas the marked outperformer amid recent gains in the complex, whilst IT follows a close second a continuation of the sector’s rally on Wall Street on Friday. Travel & Leisure names lag as some APAC countries/states/cities mull extending lockdown orders, including South Korea, Australia’s Victoria state and New Zealand’s Auckland. In terms of individual movers: BT (+5.7%) tops the Stoxx 600 board on the back of reports that the Co. is gearing up to defend itself for takeover approaches by Private Equity firms. The Co. is yet to receive a formal bid, but PE firms are reportedly looking into such a move. Meanwhile, AstraZeneca (+3.1%) is supported by reports that the Trump Admin is reportedly considering fast-tracking the Co’s COVID-19 vaccine candidate to have it in use ahead of the November election. Finally, Wirecard (-2.5%) holds its position as a laggard after being formally dropped out of the DAX 30 and replaced by Delivery Hero (+1.3%).

Top European News

  • EU Trade Chief Fights to Keep His Job After Pandemic Stumble
  • Johnson Pleads With U.K. Parents to Send Children to School
  • Italy Lockdown Success Challenged by New Europe Virus Surge
  • Italy’s Unloved Banks Move Closer to Credit-Market Redemption

In FX, the Aussie is benefiting from broad risk appetite and ongoing weakness in the Kiwi on NZ’s COVID-19 related problems and disappointing data in the form of Q2 retail sales. Hence, Aud/Usd is holding relatively firm in the high 0.7100 area, while Aud/Nzd retests 1.1000 and Nzd/Usd languishes below 0.6550 ahead of NZ trade for the first month of the current quarter on Tuesday evening. Back to the cross, a very large 1.4 bn option expiry at the 1.1000 strike may cap the upside ahead of the NY cut.

  • USD/EUR - Not quite role reversal, but a marked change of fortunes as the Dollar loses post-US PMI momentum and the DXY struggles to maintain 93.000+ status within a 93.016-266 range. Accordingly, the Euro has pared losses and is back above 1.1800, albeit tentatively as 2nd waves of the coronavirus spread across the Eurozone.
  • CAD/CHF/GBP/JPY - All narrowly mixed against the Greenback, with the Loonie towards the base of a 1.3186-52 band and deriving some traction from crude prices that are mildly bid on weather induced production cuts and site evacuations. Elsewhere, the Franc is hovering around 0.9100 and 1.0750 vs the Euro after less pronounced increases in Swiss bank sight deposits, Sterling has unwound more UK PMI gains amidst the ongoing Brexit trade stalemate, with Cable under 1.3100 and Eur/Gbp above 0.9000, while the Yen is caught between 105.94-70 parameters and 50/100 HMAs that sit at 105.84 and 105.70 respectively.
  • SCANDI/EM - Bullish risk sentiment and the aforementioned upturn in oil are keeping the Sek and Nok underpinned, while the Cnh has extended advances from a stronger PBoC Cny fix overnight through 6.9050, but the Try is lagging sub-7.3500 in wake of Fitch downgrading Turkey’s sovereign ratings outlook to negative from stable. Elsewhere, the Rub, Zar and Mxn all gleaning degrees of support from underlying commodities, while the Brl awaits Brazilian consumer confidence.

In commodities, WTI and Brent front month futures continue to eke mild gains in early European hours, with prices supported by the overall constructive tone across the market coupled by supply woes as the Gulf of Mexico is poised for a double whammy from Tropical Storms Marco and Laura – with the former set to make landfall later today and the latter on Wednesday. Reports noted that as of Sunday, around 58% of the Gulf of Mexico production has been shuttered, according to the Bureau of Safety and Environmental Enforcement – equating to around 1mln BPD. Desks also point to the fragility of refining activity amidst floods. “Although given the large amount of refined product stocks at the moment, the market would likely be able to handle any disruptions to refined product supply better this time around” analysts at ING conclude. WTI Oct meanders just north of USD 42.50/bbl (vs. low 42.23/bbl) whilst its Brent counterpart similarly resides above USD 44.50/bbl (vs. low 44.29/bbl) – with the WTI/Brent arb tightening on the aforementioned Gulf of Mexico developments. Elsewhere, spot gold and silver have recovered from overnight lows in tandem with losses in the Dollar. The yellow metal eyes USD 1950/oz vs. low 1930.30/oz) to the upside whilst spot silver nurses overnight losses to reclaim a firmer footing above USD 26.50/oz (vs. low 26.25/oz). Turning to base metals, Dalian iron ore futures closed lower by almost 2% with traders citing dampening demand for steel products amid seasonal effects and floods. Conversely, LME copper rises amid the gains in stocks, softer Dollar and with inventories falling to a 13-year low.

US Event Calendar

  • 8:30am: Chicago Fed Nat Activity Index, est. 3.7, prior 4.1

DB's Henry Allen concludes the overnight wrap

Happy Monday to our readers and hope you all had a good weekend. With Jim having been off the last two weeks and Craig’s wife almost due to give birth, I’ve been super-subbed off the bench to write your favourite email this morning. While I appreciate Jim may be twice the man that I am, or at least twice my age, I just hope you’ll think of me as the rising star of the team rather than the third choice.

The main focus over the weekend continued to be the covid-19 pandemic, as the number of confirmed global deaths surpassed 800,000. In spite of its relative success in suppressing the first wave of the virus, it’s Europe that’s begun to re-emerge as a source of concern in recent days given the latest rises in case numbers, a trend that continued through the weekend. In fact, Sunday saw France report 4,897 cases, the most since mid-April, while Italy reported 1,210, which was the most since mid-May, so investors are likely to be on the lookout for any further increases and what that might mean for the likelihood of further lockdowns or re-imposing restrictions.

Against this backdrop, President Trump announced last night that the FDA had issued an emergency use authorisation for convalescent plasma to treat hospitalised patients, which involves using blood plasma from those who’ve recovered from the virus. There were also some reports about possible vaccine developments, with the FT saying that the Trump administration were considering bypassing normal regulatory standards when it came for the Oxford/AstraZeneca vaccine, possibly with another emergency use authorisation.

In terms of the latest overnight, it was announced by New Zealand Prime Ardern that the lockdown in Auckland would be extended to midnight on August 30, having been until August 26 previously. Meanwhile in South Korea, which reported a further 266 cases in the last 24 hours, there’s concern that the country could move up to Level 3 social distancing, the highest level the country has, that would involve closing schools and recommending employees work from home. It follows a senior health official saying yesterday that the country would review the possibility. In spite of the possibility of further restrictions however, equity markets in Asia are trading higher this morning, with the Hang Seng (+1.47%) leading the way. Other indices are also up, including the Nikkei (+0.17%), Shanghai Comp (+0.18%) and the Kospi (+0.81%). And finally we could see another record high for the S&P 500 today, with futures this morning up +0.26%.

Looking to the week ahead now, the highlight is likely to be the Jackson Hole gathering on Thursday and Friday, where central bankers will be meeting (virtually this year) for the annual economic symposium. This theme on this occasion is “Navigating the Decade Ahead: Implications for Monetary Policy”, and one of the key highlights will be Fed Chair Powell’s speech on Thursday on the topic of the monetary policy review. According to our US economists, while it’s possible that the policy review results will be released along with Powell’s appearance, they think it’s more likely that he summarises the key findings and outlines the likely implications for the Fed moving forward. They think instead the review results won’t be released until the next meeting in mid-September. In addition to Powell, central bank watchers will have plenty of other speakers to look out for at the gathering, including Bank of England Governor Bailey, ECB chief economist Lane, and Bank of Canada Governor Macklem.

Turning to politics, attention will also be on the Republican National Convention taking place this week from Monday to Thursday, even if there aren’t likely to be as many market-moving headlines compared to Jackson Hole. Nevertheless, a CNN report said that President Trump would be appearing on every night of the convention, according to a Republican familiar with the convention planning, on top of his own speech planned for the Thursday night. So that could generate some news depending on the nature of any remarks. There are just over 10 weeks to go now until election day on November 3rd, and according to the polling averages, President Trump continues to lag behind Biden, with FiveThirtyEight’s average giving Biden a 9.2pt lead over Trump.

On the data side, we don’t have many top-tier releases with the US jobs report not until the following week. However, tomorrow will see both the Ifo’s business climate indicator from Germany, as well as the Conference Board’s consumer confidence from the US. On the latter, our economists think that the recent breakdown in fiscal negotiations in Congress could weigh on consumer attitudes, and see the number falling to 92.0 (vs. 92.6 in July).

Looking back to last week now, and US equity markets rose for a fourth straight week on the back of improving economic data and a further subsiding of coronavirus cases. The S&P 500 rose 0.72% (+0.34% Friday) on the week as it rose to a record high, while the tech-focused Nasdaq saw an even stronger performance over the week – up +2.65% (+0.42% Friday) – as the mega-cap growth stocks continue to pull US equities higher. In Europe, the Stoxx 600 ended the week -0.81% lower (-0.15% Friday) as economic data showed some signs of the recovery losing momentum. Other major European bourses similarly moved lower on the week as coronavirus cases continue to rise once again on the continent, with the DAX (-1.06%), CAC (-1.34%), FTSE 100 (-1.45%) and FTSE MIB (-1.66%) all losing ground.

Core sovereign bond yields fell over the course of the week after rising sharply during the week before. 10yr Treasury yields fell -8.1bps (-2.3bps Friday) to finish at 0.628%, while 10yr Bund yields declined -8.6bps (-1.1bps Friday) to -0.51%. Meanwhile the dollar rose marginally (+0.16%) as it recovered from the 2-year low it had set earlier in the week.

Against this backdrop, Friday also saw the latest round of negotiations between the UK and the EU conclude with no further progress on the key outstanding issues. The UK’s chief negotiator Frost blamed the EU’s insistence on the UK accepting continuity with EU state aid and fisheries policy before work could be done on other areas. And the EU’s chief negotiator, Michel Barnier, said that an agreement “seems unlikely” at this stage, and reiterated their existing demand that “The need for a Level Playing field is not going to go away.” The next round of talks takes place from September 7th. We saw a similar stalemate in the US with regards to fiscal stimulus talks. Republican senator Kennedy of Louisiana said late Friday that nothing’s changed on the talks, which could mean that both sides are unlikely to reach a deal even on a skinny deal before lawmakers return from recess in September.

Finally on the data front, the flash Euro Area PMIs lost momentum in August, which confounded expectations for largely unchanged readings. The composite Euro Area PMI fell to 51.6 in August, having been at 54.9 in July, while the French (-5.6pts to 51.7) and German (-1.6pts to 53.7) also saw significant declines. DB’s Peter Sidorov put out a note on Friday about this (link here), where he points out that the market shouldn’t have been that surprised, considering the signals from the recent mobility data. The UK saw a stronger move (+3.3pts to 60.3) but this simply reflects the UK climbing out of a more protracted trough rather than a higher level of activity. Elsewhere, US existing home sales rose to 5.86m (vs. 5.41m expected) from 4.72m in June. This was the strongest pace since 2006 and the highest one month percentage increase on record as low mortgage rates continue to support the real estate market.

Read More

Continue Reading

Government

Looking Back At COVID’s Authoritarian Regimes

After having moved from Canada to the United States, partly to be wealthier and partly to be freer (those two are connected, by the way), I was shocked,…

Published

on

After having moved from Canada to the United States, partly to be wealthier and partly to be freer (those two are connected, by the way), I was shocked, in March 2020, when President Trump and most US governors imposed heavy restrictions on people’s freedom. The purpose, said Trump and his COVID-19 advisers, was to “flatten the curve”: shut down people’s mobility for two weeks so that hospitals could catch up with the expected demand from COVID patients. In her book Silent Invasion, Dr. Deborah Birx, the coordinator of the White House Coronavirus Task Force, admitted that she was scrambling during those two weeks to come up with a reason to extend the lockdowns for much longer. As she put it, “I didn’t have the numbers in front of me yet to make the case for extending it longer, but I had two weeks to get them.” In short, she chose the goal and then tried to find the data to justify the goal. This, by the way, was from someone who, along with her task force colleague Dr. Anthony Fauci, kept talking about the importance of the scientific method. By the end of April 2020, the term “flatten the curve” had all but disappeared from public discussion.

Now that we are four years past that awful time, it makes sense to look back and see whether those heavy restrictions on the lives of people of all ages made sense. I’ll save you the suspense. They didn’t. The damage to the economy was huge. Remember that “the economy” is not a term used to describe a big machine; it’s a shorthand for the trillions of interactions among hundreds of millions of people. The lockdowns and the subsequent federal spending ballooned the budget deficit and consequent federal debt. The effect on children’s learning, not just in school but outside of school, was huge. These effects will be with us for a long time. It’s not as if there wasn’t another way to go. The people who came up with the idea of lockdowns did so on the basis of abstract models that had not been tested. They ignored a model of human behavior, which I’ll call Hayekian, that is tested every day.

These are the opening two paragraphs of my latest Defining Ideas article, “Looking Back at COVID’s Authoritarian Regimes,” Defining Ideas, March 14, 2024.

Another excerpt:

That wasn’t the only uncertainty. My daughter Karen lived in San Francisco and made her living teaching Pilates. San Francisco mayor London Breed shut down all the gyms, and so there went my daughter’s business. (The good news was that she quickly got online and shifted many of her clients to virtual Pilates. But that’s another story.) We tried to see her every six weeks or so, whether that meant our driving up to San Fran or her driving down to Monterey. But were we allowed to drive to see her? In that first month and a half, we simply didn’t know.

Read the whole thing, which is longer than usual.

(0 COMMENTS)

Read More

Continue Reading

International

Problems After COVID-19 Vaccination More Prevalent Among Naturally Immune: Study

Problems After COVID-19 Vaccination More Prevalent Among Naturally Immune: Study

Authored by Zachary Stieber via The Epoch Times (emphasis…

Published

on

Problems After COVID-19 Vaccination More Prevalent Among Naturally Immune: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

People who recovered from COVID-19 and received a COVID-19 shot were more likely to suffer adverse reactions, researchers in Europe are reporting.

A medical worker administers a dose of the Pfizer-BioNTech COVID-19 vaccine to a patient at a vaccination center in Ancenis-Saint-Gereon, France, on Nov. 17, 2021. (Stephane Mahe//Reuters)

Participants in the study were more likely to experience an adverse reaction after vaccination regardless of the type of shot, with one exception, the researchers found.

Across all vaccine brands, people with prior COVID-19 were 2.6 times as likely after dose one to suffer an adverse reaction, according to the new study. Such people are commonly known as having a type of protection known as natural immunity after recovery.

People with previous COVID-19 were also 1.25 times as likely after dose 2 to experience an adverse reaction.

The findings held true across all vaccine types following dose one.

Of the female participants who received the Pfizer-BioNTech vaccine, for instance, 82 percent who had COVID-19 previously experienced an adverse reaction after their first dose, compared to 59 percent of females who did not have prior COVID-19.

The only exception to the trend was among males who received a second AstraZeneca dose. The percentage of males who suffered an adverse reaction was higher, 33 percent to 24 percent, among those without a COVID-19 history.

Participants who had a prior SARS-CoV-2 infection (confirmed with a positive test) experienced at least one adverse reaction more often after the 1st dose compared to participants who did not have prior COVID-19. This pattern was observed in both men and women and across vaccine brands,” Florence van Hunsel, an epidemiologist with the Netherlands Pharmacovigilance Centre Lareb, and her co-authors wrote.

There were only slightly higher odds of the naturally immune suffering an adverse reaction following receipt of a Pfizer or Moderna booster, the researchers also found.

The researchers performed what’s known as a cohort event monitoring study, following 29,387 participants as they received at least one dose of a COVID-19 vaccine. The participants live in a European country such as Belgium, France, or Slovakia.

Overall, three-quarters of the participants reported at least one adverse reaction, although some were minor such as injection site pain.

Adverse reactions described as serious were reported by 0.24 percent of people who received a first or second dose and 0.26 percent for people who received a booster. Different examples of serious reactions were not listed in the study.

Participants were only specifically asked to record a range of minor adverse reactions (ADRs). They could provide details of other reactions in free text form.

“The unsolicited events were manually assessed and coded, and the seriousness was classified based on international criteria,” researchers said.

The free text answers were not provided by researchers in the paper.

The authors note, ‘In this manuscript, the focus was not on serious ADRs and adverse events of special interest.’” Yet, in their highlights section they state, “The percentage of serious ADRs in the study is low for 1st and 2nd vaccination and booster.”

Dr. Joel Wallskog, co-chair of the group React19, which advocates for people who were injured by vaccines, told The Epoch Times: “It is intellectually dishonest to set out to study minor adverse events after COVID-19 vaccination then make conclusions about the frequency of serious adverse events. They also fail to provide the free text data.” He added that the paper showed “yet another study that is in my opinion, deficient by design.”

Ms. Hunsel did not respond to a request for comment.

She and other researchers listed limitations in the paper, including how they did not provide data broken down by country.

The paper was published by the journal Vaccine on March 6.

The study was funded by the European Medicines Agency and the Dutch government.

No authors declared conflicts of interest.

Some previous papers have also found that people with prior COVID-19 infection had more adverse events following COVID-19 vaccination, including a 2021 paper from French researchers. A U.S. study identified prior COVID-19 as a predictor of the severity of side effects.

Some other studies have determined COVID-19 vaccines confer little or no benefit to people with a history of infection, including those who had received a primary series.

The U.S. Centers for Disease Control and Prevention still recommends people who recovered from COVID-19 receive a COVID-19 vaccine, although a number of other health authorities have stopped recommending the shot for people who have prior COVID-19.

Another New Study

In another new paper, South Korean researchers outlined how they found people were more likely to report certain adverse reactions after COVID-19 vaccination than after receipt of another vaccine.

The reporting of myocarditis, a form of heart inflammation, or pericarditis, a related condition, was nearly 20 times as high among children as the reporting odds following receipt of all other vaccines, the researchers found.

The reporting odds were also much higher for multisystem inflammatory syndrome or Kawasaki disease among adolescent COVID-19 recipients.

Researchers analyzed reports made to VigiBase, which is run by the World Health Organization.

Based on our results, close monitoring for these rare but serious inflammatory reactions after COVID-19 vaccination among adolescents until definitive causal relationship can be established,” the researchers wrote.

The study was published by the Journal of Korean Medical Science in its March edition.

Limitations include VigiBase receiving reports of problems, with some reports going unconfirmed.

Funding came from the South Korean government. One author reported receiving grants from pharmaceutical companies, including Pfizer.

Tyler Durden Fri, 03/15/2024 - 05:00

Read More

Continue Reading

International

‘Excess Mortality Skyrocketed’: Tucker Carlson and Dr. Pierre Kory Unpack ‘Criminal’ COVID Response

‘Excess Mortality Skyrocketed’: Tucker Carlson and Dr. Pierre Kory Unpack ‘Criminal’ COVID Response

As the global pandemic unfolded, government-funded…

Published

on

'Excess Mortality Skyrocketed': Tucker Carlson and Dr. Pierre Kory Unpack 'Criminal' COVID Response

As the global pandemic unfolded, government-funded experimental vaccines were hastily developed for a virus which primarily killed the old and fat (and those with other obvious comorbidities), and an aggressive, global campaign to coerce billions into injecting them ensued.

Then there were the lockdowns - with some countries (New Zealand, for example) building internment camps for those who tested positive for Covid-19, and others such as China welding entire apartment buildings shut to trap people inside.

It was an egregious and unnecessary response to a virus that, while highly virulent, was survivable by the vast majority of the general population.

Oh, and the vaccines, which governments are still pushing, didn't work as advertised to the point where health officials changed the definition of "vaccine" multiple times.

Tucker Carlson recently sat down with Dr. Pierre Kory, a critical care specialist and vocal critic of vaccines. The two had a wide-ranging discussion, which included vaccine safety and efficacy, excess mortality, demographic impacts of the virus, big pharma, and the professional price Kory has paid for speaking out.

Keep reading below, or if you have roughly 50 minutes, watch it in its entirety for free on X:

"Do we have any real sense of what the cost, the physical cost to the country and world has been of those vaccines?" Carlson asked, kicking off the interview.

"I do think we have some understanding of the cost. I mean, I think, you know, you're aware of the work of of Ed Dowd, who's put together a team and looked, analytically at a lot of the epidemiologic data," Kory replied. "I mean, time with that vaccination rollout is when all of the numbers started going sideways, the excess mortality started to skyrocket."

When asked "what kind of death toll are we looking at?", Kory responded "...in 2023 alone, in the first nine months, we had what's called an excess mortality of 158,000 Americans," adding "But this is in 2023. I mean, we've  had Omicron now for two years, which is a mild variant. Not that many go to the hospital."

'Safe and Effective'

Tucker also asked Kory why the people who claimed the vaccine were "safe and effective" aren't being held criminally liable for abetting the "killing of all these Americans," to which Kory replied: "It’s my kind of belief, looking back, that [safe and effective] was a predetermined conclusion. There was no data to support that, but it was agreed upon that it would be presented as safe and effective."

Carlson and Kory then discussed the different segments of the population that experienced vaccine side effects, with Kory noting an "explosion in dying in the youngest and healthiest sectors of society," adding "And why did the employed fare far worse than those that weren't? And this particularly white collar, white collar, more than gray collar, more than blue collar."

Kory also said that Big Pharma is 'terrified' of Vitamin D because it "threatens the disease model." As journalist The Vigilant Fox notes on X, "Vitamin D showed about a 60% effectiveness against the incidence of COVID-19 in randomized control trials," and "showed about 40-50% effectiveness in reducing the incidence of COVID-19 in observational studies."

Professional costs

Kory - while risking professional suicide by speaking out, has undoubtedly helped save countless lives by advocating for alternate treatments such as Ivermectin.

Kory shared his own experiences of job loss and censorship, highlighting the challenges of advocating for a more nuanced understanding of vaccine safety in an environment often resistant to dissenting voices.

"I wrote a book called The War on Ivermectin and the the genesis of that book," he said, adding "Not only is my expertise on Ivermectin and my vast clinical experience, but and I tell the story before, but I got an email, during this journey from a guy named William B Grant, who's a professor out in California, and he wrote to me this email just one day, my life was going totally sideways because our protocols focused on Ivermectin. I was using a lot in my practice, as were tens of thousands of doctors around the world, to really good benefits. And I was getting attacked, hit jobs in the media, and he wrote me this email on and he said, Dear Dr. Kory, what they're doing to Ivermectin, they've been doing to vitamin D for decades..."

"And it's got five tactics. And these are the five tactics that all industries employ when science emerges, that's inconvenient to their interests. And so I'm just going to give you an example. Ivermectin science was extremely inconvenient to the interests of the pharmaceutical industrial complex. I mean, it threatened the vaccine campaign. It threatened vaccine hesitancy, which was public enemy number one. We know that, that everything, all the propaganda censorship was literally going after something called vaccine hesitancy."

Money makes the world go 'round

Carlson then hit on perhaps the most devious aspect of the relationship between drug companies and the medical establishment, and how special interests completely taint science to the point where public distrust of institutions has spiked in recent years.

"I think all of it starts at the level the medical journals," said Kory. "Because once you have something established in the medical journals as a, let's say, a proven fact or a generally accepted consensus, consensus comes out of the journals."

"I have dozens of rejection letters from investigators around the world who did good trials on ivermectin, tried to publish it. No thank you, no thank you, no thank you. And then the ones that do get in all purportedly prove that ivermectin didn't work," Kory continued.

"So and then when you look at the ones that actually got in and this is where like probably my biggest estrangement and why I don't recognize science and don't trust it anymore, is the trials that flew to publication in the top journals in the world were so brazenly manipulated and corrupted in the design and conduct in, many of us wrote about it. But they flew to publication, and then every time they were published, you saw these huge PR campaigns in the media. New York Times, Boston Globe, L.A. times, ivermectin doesn't work. Latest high quality, rigorous study says. I'm sitting here in my office watching these lies just ripple throughout the media sphere based on fraudulent studies published in the top journals. And that's that's that has changed. Now that's why I say I'm estranged and I don't know what to trust anymore."

Vaccine Injuries

Carlson asked Kory about his clinical experience with vaccine injuries.

"So how this is how I divide, this is just kind of my perception of vaccine injury is that when I use the term vaccine injury, I'm usually referring to what I call a single organ problem, like pericarditis, myocarditis, stroke, something like that. An autoimmune disease," he replied.

"What I specialize in my practice, is I treat patients with what we call a long Covid long vaxx. It's the same disease, just different triggers, right? One is triggered by Covid, the other one is triggered by the spike protein from the vaccine. Much more common is long vax. The only real differences between the two conditions is that the vaccinated are, on average, sicker and more disabled than the long Covids, with some pretty prominent exceptions to that."

Watch the entire interview above, and you can support Tucker Carlson's endeavors by joining the Tucker Carlson Network here...

Tyler Durden Thu, 03/14/2024 - 16:20

Read More

Continue Reading

Trending